Podcast: Cereno Scientific Turns To Old Drug For Rare Cardiopulmonary Diseases – InVivo

CEO Sten R. Sörensen talks to David Wild, In Vivo

Cereno Scientific is betting that an old epilepsy drug holds the key to transforming treatment for some of the most challenging rare cardiovascular and pulmonary diseases.

The Sweden-based biotech has built its platform around epigenetic modulation through HDAC inhibition—a mechanism that’s been hiding in plain sight for decades but never applied to these devastating conditions.

In this episode of the In Vivo Podcast, CEO Sten Sörensen walks us through the company’s journey from academic discovery to clinical validation, including compelling Phase IIa data in pulmonary arterial hypertension that prompted physicians to request compassionate use access.

With fast-track designation from the US FDA in hand and a second program advancing in idiopathic pulmonary fibrosis, Sörensen discusses how the company’s repurposing strategy could deliver disease-modifying therapies to patient populations desperate for options beyond current vasodilators.

He also shares insights on the challenges of financing rare disease programs and the strategic decisions ahead as Cereno aims to complete pivotal trials within the next three to five years.

Listen here >